Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02053831 · ClinicalTrials.gov registry record

GalaFlex Mesh in Facelift

A clinical trial of Superficial Musculoaponeurotic System (SMAS) Procedure, sponsored by C. R. Bard.

Completed
Registry status
15
Enrollment target
3
Study locations

NCT02053831 is a study of Superficial Musculoaponeurotic System (SMAS) Procedure that has completed, run by C. R. Bard. The registered enrollment target is 15 participants. The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02053831, a study of Superficial Musculoaponeurotic System (SMAS) Procedure, has completed, sponsored by C. R. Bard.

COMPLETED
Registry status
15 participants
Enrollment target
3
Study locations

Study Summary

In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area. GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.

Study Locations (3)

Illinois

  • The Few Institute for Aesthetic Plastic Surgery - Chicago
  • Eye and Ear Institute - Chicago

Florida

  • Ponte Vedra Plastic Surgery - Ponte Vedra Beach

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2011-11
Est. Completion 2014-06

Sponsor

C. R. Bard

75 total trials

What the Registry Record Tells You About NCT02053831

The ClinicalTrials.gov registry entry for NCT02053831 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Superficial Musculoaponeurotic System (SMAS) Procedure appearing as the primary indexed condition, and to 0 interventions.

NCT02053831 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT02053831 about?

NCT02053831 is a clinical study titled "GalaFlex Mesh in Facelift". In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area. GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.

What is the current status of trial NCT02053831?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2011-11. Estimated completion is 2014-06.

What conditions does trial NCT02053831 study?

This clinical trial studies the following conditions: Superficial Musculoaponeurotic System (SMAS) Procedure.

Who is sponsoring clinical trial NCT02053831?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02053831 being conducted?

This trial has 3 study locations across Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.